Bolt Biotherapeutics, Inc. (NASDAQ:BOLT – Get Free Report) was the recipient of a significant decline in short interest during the month of September. As of September 15th, there was short interest totalling 195,600 shares, a decline of 14.2% from the August 31st total of 228,000 shares. Based on an average trading volume of 162,200 shares, the short-interest ratio is presently 1.2 days. Approximately 0.8% of the shares of the company are sold short.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in Bolt Biotherapeutics stock. Assenagon Asset Management S.A. acquired a new stake in Bolt Biotherapeutics, Inc. (NASDAQ:BOLT – Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 34,488 shares of the company’s stock, valued at approximately $26,000. Assenagon Asset Management S.A. owned 0.09% of Bolt Biotherapeutics as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 86.70% of the company’s stock.
Bolt Biotherapeutics Stock Performance
Shares of Bolt Biotherapeutics stock traded up $0.04 during trading on Friday, reaching $0.62. The company’s stock had a trading volume of 244,673 shares, compared to its average volume of 175,730. The company has a 50-day moving average price of $0.68 and a two-hundred day moving average price of $0.87. Bolt Biotherapeutics has a fifty-two week low of $0.55 and a fifty-two week high of $1.56. The firm has a market cap of $23.65 million, a PE ratio of -0.37 and a beta of 0.93. The company has a current ratio of 4.28, a quick ratio of 4.28 and a debt-to-equity ratio of 0.19.
Analyst Ratings Changes
Separately, HC Wainwright reaffirmed a “neutral” rating on shares of Bolt Biotherapeutics in a report on Thursday, August 15th. Five research analysts have rated the stock with a hold rating, Based on data from MarketBeat, Bolt Biotherapeutics currently has a consensus rating of “Hold” and a consensus price target of $3.50.
Check Out Our Latest Stock Report on BOLT
About Bolt Biotherapeutics
Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.
Featured Articles
- Five stocks we like better than Bolt Biotherapeutics
- 10 Best Airline Stocks to Buy
- CarMax’s Impressive Rally: What Investors Should Watch Next
- Best Stocks Under $10.00
- MarketBeat Week in Review – 9/23 – 9/27
- Earnings Per Share Calculator: How to Calculate EPS
- Wake Up to This Biotech Stock That Still Has Big Potential Upside
Receive News & Ratings for Bolt Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bolt Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.